Business Insider's global editor-in-chief Nicholas Carlson will step down from his role at the digital news website later this summer, he said in a post on social media firm X on Tuesday. Carlson, who has been in the role since 2017, has spent more than 15 years at the news website, which is owned by German publishing giant Axel Springer SE. "My move has nothing to do with any criticism of our journalism," Carlson said in the memo that he also shared on LinkedIn.
“Antoinette impacted our agency with her sweet nature, kind heart, warm smile, and pride in being the voice on the other end of a call for help.”
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa